Friday, OraSure Technologies Inc. (OSUR) said its OraQuick Hepatitis C Rapid Antibody Test has been approved by the U.S. Food and Drug Administration for use in detecting HCV antibodies in venous whole blood specimens. This makes it the first rapid HCV test approved by the FDA for use in the United States, the company added.
The noted that the OraQuick HCV is the rapid, point-of-care test for the detection of antibodies to the hepatitis C virus in venous whole blood specimens that is approved by the FDA. The test, which utilizes the OraQuick technology platform, provides results in 20 minutes. The OraQuick HCV Rapid Antibody Test is the latest rapid test manufactured by OraSure to receive FDA approval.
OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices.
OSUR is currently trading at $5.31, up $0.46 or 9.48%, on a volume of 17,590 shares on the Nasdaq.
For comments and feedback: editorial@rttnews.com